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BACKGROUND: The aim of this study was to evaluate the radiosensitising effect of gemcitabine, in terms of cell-cycle progression,
induction of apoptosis, and to investigate the molecular events regulating apoptosis.
METHODS: Tumour cells were treated with gemcitabine, radiation, or the combination. 0–72h after treatment, cells were collected for
cell-cycle analysis and apoptosis determination. Caspase 8 and 9, Bid and tBid expression were determined by western blot. The
mitochondrial membrane potential was determined using flow cytometry. An RT
2 Profiler PCR Array for human apoptotic genes was
performed after the combination or TRAIL treatment.
RESULTS: Gemcitabine and radiation resulted in an early S-phase block immediately after treatment, after which the cells moved
synchronously through the cell cycle. When cell-cycle distribution returned to pre-treatment levels, an increased induction of
apoptosis was observed with activation of caspase 8 and 9 and a reduction of the mitochondrial membrane potential. Gene
expression after treatment with radiosensitising conditions was comparable with expression after the TRAIL treatment.
CONCLUSION: A role for the cell-cycle perturbations and the induction of apoptosis could be attributed to the radiosensitising effect of
gemcitabine. Apoptosis induction was comparable with the apoptotic pathway observed after the TRAIL treatment, that is the
involvement of the extrinsic apoptosis pathway.
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Killing of tumour cells by cytotoxic therapies, such as chemo-
therapy and g-irradiation, is in some tumours predominantly
mediated by triggering apoptosis (Brown and Wouters, 2001;
Debatin and Krammer, 2004). This might occur either as a primary
event induced by therapy or as a secondary event after lethal
damage to the cell (Tannock and Lee, 2001). A family of cystein-
dependent aspartate directed proteases, called caspases, is
responsible for the proteolytic cleavage of cellular proteins leading
to the characteristic apoptotic features. Currently, two pathways
for activating caspases have been studied in detail, that is
the mitochondrial ‘intrinsic’ pathway and the transmembrane
‘extrinsic’ pathway. Both pathways share the same effector
caspases (caspase 3, 6, and 7).
The intrinsic pathway is under control of the Bcl-2 protein
family. Permeabilisation of the outer mitochondrial membrane
induces the leakage of proapoptotic molecules from the mitochon-
drial intermembrane space. In the cytosol, cytochrome c induces
the oligomerisation of apoptosis protease activating factor 1
(Apaf-1) in the presence of ATP or dATP. Apoptosis protease
activating factor 1 oligomers recruit procaspase 9 molecules in a
complex called the ‘apoptosome’. The release of mature caspase 9
activates additional caspase 9 molecules as well as caspase 3 and 7.
In turn, caspase 3 activates downstream caspase cascades. At the
same time, the release of Smac/DIABLO and HtrA2/Omi neutra-
lises the inhibitory effects of inhibitors of apoptosis proteins on
caspase 3, 7, and 9.
Plasma membrane receptors for triggering external apoptosis
signalling belong to the tumour necrosis factor (TNF)-receptor
superfamily. The best-studied death receptor is Fas; binding of Fas
ligand (FasL) leads to receptor trimerisation and recruitment of
specific adaptor proteins. The Fas receptor contains a death
domain (DD) in its cytoplasmatic region, which interacts with the
adaptor protein, Fas-associating DD protein (FADD), forming a
death receptor-induced signalling complex (DISC). Besides a DD,
FADD contains a death effector domain (DED) and this recruits
the DED-containing procaspase 8 into the DISC. Procaspase 8 will
be proteolytically activated to the enzymatically active caspase 8,
which in turn will activate downstream effector caspases. Other
death receptors activate caspases in a similar manner. Depending
on the cell type, activated caspase 8 induces apoptosis by two
different signalling pathways. In type I cells, large amounts of
active caspase 8 formed at the DISC induce direct activation of
procaspase 3 independently of mitochondria. In type II cells, the
presence of only very little DISC and small amounts of caspase 8 is
insufficient to activate procaspase 3 directly and therefore
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sapoptosis pathway is required. Instead, caspase 8 cleaves the ‘BH3-
only protein’ Bid, generating an active fragment (tBid) that
activates the mitochondrial death pathway (Green, 2000; Debatin
and Krammer, 2004; Fulda and Debatin, 2006).
The nucleoside analogue gemcitabine (dFdC) has shown
promising clinical effectiveness against a range of solid tumours.
The cytotoxic effect of this agent is mediated by the induction of
apoptotic cell death as shown by Huang and Plunkett (1995a). In
addition, gemcitabine has shown both in laboratory and clinical
studies to be a potent radiosensitiser (Pauwels et al, 2005a), but the
exact mechanism of radiosensitisation remains as yet unknown.
Interesting in that respect is the fact that gemcitabine-induced
accumulation of cells in the S phase appears to be required for
maximal radiosensitisation (Pauwels et al, 2005a; Shewach and
Lawrence, 2007). Taking into account that the S phase is not
reported to be the most radiosensitive phase of the cell cycle
(Sinclair, 1972; Tang et al, 1997), the question remains whether the
influence on the cell cycle indeed plays a role in radiosensitisation.
Studies investigating the radiosensitising effect of gemcitabine
hypothesised that the ability of cells to progress through the
S phase after gemcitabine and radiation may be a key for
radiosensitisation to occur (Ostruszka and Shewach, 2000; Mose
et al, 2003). It may suggest that cells progressing beyond the
S-phase block might accumulate proapoptotic signals, caused by
both radiation and gemcitabine, resulting in increased cell death. It
has also been hypothesised that radiosensitisation by gemcitabine
is the result of lowering the threshold for radiation-induced
apoptosis (Doyle et al, 2001).
Therefore, the aims of this study were to evaluate the cell-cycle
progression and to study the induction of apoptosis, in two types
of human tumour cells, after treatment with gemcitabine and/or
radiotherapy. In addition, the molecular events that regulate
apoptosis were explored. Understanding these events may provide
important new opportunities for pathway-based rational therapy
and for drug development.
MATERIALS AND METHODS
Cell lines
The cell lines used in this study were ECV304 (mutant (mt) p53),
a human epidermoid bladder cancer cell line and H292 (wild-
type (wt) p53), a human mucoepidermoid lung cancer cell
line. H292 was cultured in RPMI-1640 medium, supplemented
with L-glutamine, sodium pyruvate, and 10% fetal calf serum
(Invitrogen, Merelbeke, Belgium). ECV304 was cultured in
medium-199 supplemented with 10% fetal calf serum. Cultures
were maintained in exponential growth in a humidified atmo-
sphere at 371Cu n d e r5 %C O 2/95% air. For subsequent experi-
ments, cells were collected by trypsinisation, counted, and plated
as specified below.
As we reported earlier, the IC50 value of 24h treatment with
gemcitabine was 3.05±0.49 for ECV304 cells and 7.99±0.77 for
H292 cells (Pauwels et al, 2003a).
Cell survival after treatment with gemcitabine and
radiation
Cells were plated in 48-well plates and treated as we described
earlier (Pauwels et al, 2003a,c, 2005b). Gemcitabine was added
during 24h, immediately followed by radiation or immediately
after radiation (room temperature, 0–8Gy, linear accelerator).
After 7 days, the survival was determined by the sulforhodamine B
(SRB) assay as described earlier (Pauwels et al, 2003a,b). This
method was comparable with the clonogenic assay taking in
account some critical aspects (Pauwels et al, 2003b).
Cell cycle effect of gemcitabine and/or radiation
Cells were plated in 6-well plates as described earlier (Pauwels
et al, 2003c). To ensure exponential growth during the experi-
ments, seeding densities ranged from 0.3 to 0.5 10
5 cells per well
depending of culture time after treatment. Cells were treated with
8n M of gemcitabine for 24h, or irradiated (4Gy), or treated with
8n M gemcitabine for 24h immediately before 4Gy radiation.
Medium was replaced immediately after radiation, and the cell
cycle was monitored for the following 72h, by measuring cellular
DNA content as published earlier (Pauwels et al, 2003c).
Determination of apoptosis by Annexin V staining, TUNEL
assay, and caspase 3 activity assay
Cells were plated in 75cm
2 culture flasks to ensure exponential
growth during the experiments. After plating and a 24h recovery
period, ECV304 and H292 cells were treated with IC25 (2 and 4nM,
respectively) or IC90 (8 and 18nM, respectively) concentrations
gemcitabine for 24h, immediately before or after radiotherapy
(2 and 6Gy). Seventy-two hours later, both adherent and detached
cells were collected.
Annexin V staining was performed using Annexin V-FITC
apoptosis detection kit I (Becton-Dickinson Pharmingen, Erem-
bodegem, Belgium) in accordance with the manufacturer’s
instructions. Briefly, cells were washed twice with cold PBS,
counted and 1 10
6 cells were collected and resuspended in 1ml
binding buffer (10mM HEPES/NaOH, 140mM NaCl, 25mM CaCl2).
A measure of 100ml of this solution was mixed with 5ml Annexin V
conjugated with fluorescein isothiocyanate (Annexin V-FITC) and
5ml propidiumiodide (PI). The cells were gently vortexed and
incubated for 15min at room temperature. Then, 400ml binding
buffer was added. Analysis of green (Annexin V-FITC) and red
(PI) fluorescence was performed in a FACScan flow cytometer
(Becton-Dickinson).
To determine apoptosis by TUNEL assay, 2 10
6 cells were
collected and evaluated using in situ cell death detection kit,
Fluorescein (Roche, Vilvoorde, Belgium) in accordance with the
manufacturer’s instructions. Briefly, cells were washed twice with
PBS/1%BSA at 41C. Then, 1ml fixation solution was added to the
cell suspension (1% formaldehyde) for 30min on ice, while
shaking. Cells were centrifuged (5min, 1200r.p.m.) and washed
once with PBS. Cells were permeabilised in 70% ethanol for at least
30min at  201C until colouring. Cells were washed twice with PBS
and incubated in TUNEL reaction mixture (dUTP-FITC) for
60min at 371C. Cells were washed again twice with PBS and
resuspended in 500ml PBS containing 5ml PI/RNase (500mgml
 1
with 0.1% RNase). Samples were analysed in a FACScan flow
cytometer, measuring green (dUTP-FITC incorporated in frag-
mented DNA) and red (PI binding to DNA) fluorescence of nuclei
of individual cells.
Caspase 3 activity was determined using the colorimetric
caspase 3 assay (Sigma Aldrich, Bornem, Belgium). This assay is
based on the hydrolysis of the peptide substrate acetyl-Asp-Glu-
Val-Asp p-nitroanilide (Ac-DEVD-pNA) by caspase 3, resulting in
the release of pNA. pNA has a high absorbance at 405nm
(enm¼10.5). The concentration of pNA released from the substrate
is calculated from a calibration curve prepared with defined pNA
solutions; 10
7 control and treated cells were collected. Cells were
washed with PBS and evaluated according to the manufacturer’s
instructions.
Mitochondrial transmembrane potential measurement
The mitochondrial membrane potential (Dcm) was flow cytome-
trically determined using a mitochondrial-sensitive probe: tetra-
methylrhodamine methylester (TMRM). It accumulates in the
mitochondria and the transmembrane distribution of the dye is
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sdirectly related to the membrane potential. Tetramethylrhodamine
methylester does not accumulate in depolarised mitochondria. The
extent of its uptake, measured as fluorescence intensity reflects
Dcm.
Cells were plated in 75cm
2 culture flasks as described above.
Seventy-two hours after treatment with gemcitabine (IC25 and
IC90) and/or radiotherapy (2 and 6Gy), both adherent and
detached cells were collected. After washing in PBS, cells were
incubated with 200nM TMRM and 5ml Annexin V-FITC for 15min
at 371C and orange (TMRM) and green fluorescence were
measured on a FACScan flow cytometer.
Western blot and immunodetection
Cells were plated in 75cm
2 culture flasks to ensure exponential
growth during the experiments. After plating and a 24h recovery
period, cells were treated with gemcitabine alone (IC25 and IC90),
radiation alone (2–6Gy), or the combination. At different time
points after radiation, both adherent and detached cells were
collected by trypsinisation; 10
6 cells were washed with PBS and
resuspended in 100ml laemmli sample buffer (Bio-Rad, Nazareth,
Belgium). Western blotting and immunodetection were performed
as described earlier (Pauwels et al, 2005b). Primary antibodies
were 1/100 anti-caspase 8 (Ab-3) (Calbiochem, Leuven, Belgium),
1/100 anti-caspase 9 (Ab-2) (Calbiochem), 1/1000 anti-Bid and
truncated Bid (tBid) (Bioke ´, Leiden, The Netherlands). Secondary
antibodies were 1/1000 Anti-rabbit IgG peroxidase conjugate and
1/1000 anti-mouse IgG horse-radish-peroxidase linked (Bioke ´).
Human apoptosis PCR array
A PCR array was used for gene expression analysis, taking
advantage of real-time PCR performance, combined with the
ability to detect the expression of many genes simultaneously.
Cells were plated in 75cm
2 culture flasks as described above.
Seventy-two hours after treatment, total RNA samples were
isolated from 4 10
6 control and treated cells (IC90–6Gy) or cells
treated with an inducer of the extrinsic pathway (200ngml
 1
TRAIL, 6h, Calbiochem), using RNeasy Mini Kit (Qiagen, Venlo,
The Netherlands). TRAIL-induced apoptosis was first confirmed
after Annexin V staining (data not shown). The cDNAs were
reversed transcribed from RNA using ReactionReady First Strand
cDNA Synthesis Kit (SABiosciences, Tebu-Bio, Boechout,
Belgium). Comparison of the relative expression of 84 apoptosis-
related genes was characterised by human apoptosis PCR array
(SABiosciences) and the RT
2real-time SYBR Green/Rox PCR
Master mix (SABiosciences) on a 7000 real-time PCR System
(Applied Biosystems, Lennik, Belgium). The array includes the
TNF ligands and their receptors, members of the Bcl-2 family,
caspases, IAP, TRAF, CARD, DD, DED, and CIDE family, as well as
genes involved in the p53 and ATM pathways (Supplementary
Figure 1).
Data analysis
Survival rates were calculated by mean OD (optical density) of
treated cells/mean OD of control cells 100%. The radiation
survival curves were fitted according to the linear quadratic model:
survival¼exp( aD–bD
2), using Winnonlin (Pharsight, Mountain
View, CA, USA). The radiosensitising effect was represented by the
dose enhancement factor (DEF): ID50( dFdC)/ID50(þdFdC). For
the determination of synergism, the combination index (CI) was
calculated by the Chou–Talalay equation (Pauwels et al, 2003a),
using CalcuSyn (Biosoft, Cambridge, UK). A CI value between 0.9
and 1.1 indicates only additivity. Moderate synergism is depicted
by CI values between 0.7 and 0.9, synergism by CI values below 0.7.
Flow cytometric data were analysed using Cell Quest (Becton-
Dickinson) software.
Unless otherwise indicated, all data are presented as the
mean±s.d. All experiments were performed at least three times.
A two-sample t-test and two-way ANOVA were used to determine
statistical significance (Po0.05). Two-way ANOVA was used to
study the impact of the concentration of gemcitabine, doses
radiotherapy, and treatment schedule on the outcome parameter
(cell survival). Post hoc comparisons revealed which groups
differed significantly from one another. A correlation coefficient
was calculated between apoptosis induction and cell survival.
To analyse the data of the PCR array, a centroid-mediated
classification algorithm was applied. Therefore, two centroids,
representing the average gene expression pattern of the apoptosis-
related genes with or without treatment with TRAIL, were
calculated for H292 and ECV304 cells separately. Thereafter, the
agreement between the apoptosis-related gene expression pattern
of control cells or cells treated with gemcitabine and radiotherapy
and the apoptosis-related gene expression pattern with or without
treatment with TRAIL were quantified for each cell line. Therefore,
Pearson correlation coefficients between the apoptosis-related
expression pattern of each centroid (TRAIL-treated and TRAIL-
untreated) and the apoptosis-related expression patterns of the cell
lines (control or gemcitabine and radiation-treated cells) were
calculated. Then, for each centroid separately, the correlation
coefficients were compared between the control and the treatment
conditions.
Next, P-values were calculated to identify individual genes with
gene expression differences between the untreated and treated
experiments for each cell line separately. Using the global test
(Goeman et al, 2004), geneplots of the differentially expressed
genes were generated to investigate the relative overexpression of
each gene present in the gene list of differentially expressed genes.
In addition, to account for the false discovery rate, the global test
was used to calculate a Z-score for each of the differentially
expressed genes between treated and untreated experiments. The
Z-score represents the difference between the observed and
expected (calculated by random class label permutations) gene
expression differences between treated and untreated cells,
normalised to the standard deviation of the distribution of
expected gene expression differences.
RESULTS
Cell survival after treatment with gemcitabine and
radiation
A clear concentration-dependent radiosensitising effect of gemci-
tabine was observed in ECV304 and H292 cells, when cells
were treated during 24h with gemcitabine before radiotherapy
(Figure 1). This radiosensitising effect was not observed when cells
were treated with gemcitabine during 24h immediately after
irradiation. When gemcitabine treatment preceded radiation, DEFs
ranged from 1.39 to 3.05 (CI values 1.05–0.65) in ECV304 cells and
from 1.20 to 2.67 (CI values 1.21–0.76) in H292 cells (Pauwels et al,
2003a). When gemcitabine followed radiotherapy DEFs ranged
from 0.98 to 1.02 and from 1.12 to 1.19 for ECV304 and H292 cells,
respectively, with CI values above 0.827 for ECV304 and above
1.071 for H292 cells. Statistical analysis using two-way ANOVA
revealed that cell survival was significantly influenced by the
concentration of gemcitabine, the dose of radiation, and the
treatment schedule (gemcitabine before or after radiotherapy) in
both cell lines. Post hoc analysis showed in ECV304 significant
differences among all radiation doses and also among 0, 1, and
2n M gemcitabine. No significant difference was observed between
2 and 4nM gemcitabine (P¼0.865). In H292 cells, significant
differences were observed among all radiation doses and between
0 and 4nM gemcitabine. No significant differences were observed
among 4, 6, and 8nM gemcitabine (P40.724).
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radiation
In Figure 2, the distribution of ECV304 and H292 cells over the cell
cycle phases at different time points is shown. Without treatment,
the distribution of cells over the different phases is very similar over
time. Treatment with gemcitabine (8nM) alone resulted in an early
S-phase block immediately after treatment, as we reported earlier
(Pauwels et al, 2003c) and 8h later, the amount of S-phase cells
increased and 48h after treatment the cell cycle distribution
returned to pre-treatment levels. In ECV304 cells, radiation (4Gy)
caused a G2/M block, which was maximal 16h after radiotherapy. In
H292 cells, radiotherapy resulted in a G2/M block, which was also
maximal 16h after radiotherapy, whereas the amount of G1 cells
remained roughly constant at the expense of S-phase cells. 48h after
radiation, the cell cycle distribution returned to pre-treatment levels.
Treatment with the combination of gemcitabine and radiotherapy
resulted in an early S-phase block immediately after treatment, both
in ECV304 and in H292 cells. This block was followed by a
synchronous movement of the cells to the G2/M phase. The G2/M
block was maximal 24h after treatment, being 8h later than after
radiotherapy alone. The cell cycle distribution returned to pre-
treatment levels 72h after combination treatment.
Analysis of apoptosis induction after treatment with
gemcitabine and/or radiotherapy
The amount of apoptotic cells was determined using Annexin V
staining and caspase 3 activity assay. For ECV304 cells, apoptosis
induction was also evaluated by TUNEL assay. In Table 1, the
amount of Annexin V-positive cells is summarised. For both
ECV304 and H292 cells, the amount of early apoptotic cells
increased with the combination gemcitabine and radiation. More
apoptotic cells were observed with a higher concentration
gemcitabine or higher radiation dose. Similar results were
observed with TUNEL assay for ECV304 cells (Figure 3A). In fact,
treatment with 8nM of gemcitabine and 6Gy radiation resulted in
more than 50% TUNEL-stained cells 72h after treatment.
Using the caspase 3 activity assay, these results were confirmed.
Caspase 3 activity increased with the combination of gemcitabine
and radiotherapy (Figure 3B).
Although apoptosis was determined when cells were treated with
gemcitabine immediately after radiation, Annexin V staining was
less pronounced than when gemcitabine treatment preceded
radiation (Table 1). In H292 cells, this is significantly different.
The amount of apoptosis of ECV304 and H292 cells was
negatively correlated to the cell survival observed with the SRB test
for the IC25 values of gemcitabine (the correlation coefficient was
 0.8 and  0.9 for ECV304 and H292 cells, respectively, when
apoptosis was determined with Annexin V staining). This means
that there is a positive correlation between apoptosis induction
and the amount of cell kill using lower concentrations of
gemcitabine. The correlation coefficient for the IC90 values could
not be calculated because this concentration was not used in the
SRB test because of high toxicity.
Immunodetection of caspase 8, caspase 9, Bid and tBid
after treatment with gemcitabine and radiotherapy
To investigate the apoptotic pathway under radiosensitising
conditions, the expression of caspase 8 and 9, initiator caspases
of, respectively, the receptor and mitochondrial-mediated pathway
were investigated at the moment apoptosis was observed, that is
72h after combination treatment.
Gemcitabine alone induced the activation of caspase 8 in H292
and ECV304 cells. In H292, both IC25 and IC90 gemcitabine
concentrations resulted in caspase 8 cleaving. No activation of
caspase 9 could be shown after incubation with gemcitabine alone.
A similar effect was observed after irradiation alone (data not
shown). When cells were treated with the combination of
gemcitabine and radiotherapy, cleaving products of both caspase 8
and 9 were observed. This could mean that both the extrinsic and
intrinsic apoptotic pathway were involved in the apoptotic cell
death. Therefore, Bid and tBid expression were determined.
However, Bid expression was quite variable and did not show any
relationship with treatment. No tBid could be shown (Figure 3C).
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Figure 1 Radiation dose–response curves of ECV304 and H292 cells after treatment with gemcitabine (0–8nM) during 24h, immediately before or after
radiotherapy (0–8Gy).
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sMeasurement of the transmembrane mitochondrial
potential
In Figure 3D, TMRM-positive cells and Annexin-V-positive
cells with a reduction in TMRM fluorescence (loss of Dcm) are
shown. Treatment with gemcitabine, radiotherapy but especially
with the combination of both did increase the amount of cells
with a loss of mitochondrial potential. Thus, induction of
apoptosis under radiosensitising conditions is accompanied by
decrease in Dcm.
Human apoptosis PCR array
In Figure 4A, the correlation coefficient of control and treated cells
with the centroids (no TRAIL or TRAIL) are shown. When the
correlation coefficient of treated cells (IC90-6Gy) and the centroid
without TRAIL are compared with the correlation coefficients of the
treated cells (IC90-6Gy) and the centroid with TRAIL, the latter
correlation coefficients are significantly elevated. When the curve
slopes were determined and compared for each cell line separately,
there was a significant difference for ECV304 (P¼0.002), whereas
there was only a trend to difference for H292 cells (P¼0.095). This
means that the gene expression pattern of ECV304 after treatment
with the combination of gemcitabine and irradiation was compar-
able with the gene expression pattern of cells treated with TRAIL.
In H292 cells, gene expression pattern using radiosensitising
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Figure 2 Cell cycle analysis at different time points after treatment with gemcitabine (8nM), radiotherapy (4Gy), or the combination of gemcitabine and
radiotherapy.
Table 1 Percentage Annexin V-positive (early apoptotic) ECV304 and
H292 cells 72h after treatment with gemcitabine for 24h and/or
radiotherapy
dFdC immediately
before RT 0Gy 2Gy 6Gy
ECV304
0n M 9.17±2.38 10.86±1.74 18.76±5.87*
2n M 10.20±1.36 11.18±2.33 17.19±2.30
w
8n M 14.28±1.68* 18.34±8.41
y 31.83±7.31
y,||
H292
0n M 4.00±1.55 6.52±2.39 13.53±4.04*
4n M 4.77±0.72 5.55±1.51 15.61±1.20
ww
18nM 20.06±5.09* 26.94±5.34** 38.26±7.82
||,yy
dFdC immediately after RT
ECV304
0n M 12.67±2.93 12.56±4.50 23.16±2.70
2n M 5.73±3.40 13.06±4.57 19.18±7.33
8n M 7.35±5.35 7.30±4.13 17.18±7.07
H292
0n M 4.02±1.94 5.68±4.37 9.49±4.66
4n M 3.42±1.91 2.20±0.75 5.60±3.12
18nM 5.26±1.24 7.24±5.55 11.42±1.33
yy
*Po0.05 vs 0n M+0Gy,
wPo0.05 vs 2n M+0Gy,
yPo0.05 vs 8n M+0Gy,
||Po0.05 vs
0n M+6Gy, **Po0.05 vs 0n M+2Gy,
wwPo0.05 vs 4n M+0Gy,
yyPo0.05 vs
18nM+0Gy.
Radiosensitisation by gemcitabine and apoptosis
B Pauwels et al
632
British Journal of Cancer (2009) 101(4), 628–636 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sconditions was also comparable with the pattern after treatment
with TRAIL, however, to a lesser extent then in ECV304 cells.
In Figure 4B, the individual genes with significant gene
expression differences between the untreated (0nM–0Gy) and
treated (IC90-6Gy) experiments are shown (Po0.05). In ECV304
cells, expression of caspase 6, BID, BIRC3, GADD45A, and CARD8
was more pronounced in samples of treated cells. In H292 cells,
GADD45A, caspase 8, caspase 4, caspase 5, TNFRSF9, PYCARD,
BCL2L1, and Fas showed a higher expression in cells after
treatment with gemcitabine and radiotherapy. All these genes are
pro-apoptotic genes, except BIRC3 for ECV304 cells and BCL2L1
for H292 cells.
DISCUSSION
In this study, the role of apoptosis in the radiosensitising effect of
gemcitabine was investigated thoroughly. An increased induction
of apoptosis was observed using radiosensitising conditions as a
result of activation of the extrinsic or receptor-mediated apoptosis
pathway. This is the first study investigating the apoptosis pathway
after treatment of tumour cells with radiosensitising conditions of
gemcitabine.
Apoptosis has shown to be a significant mode of cell death after
tumour treatment and may play a significant role in drug and
radiation enhancement (Tolis et al, 1999; Ostruszka and Shewach,
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Figure 3 (A) TUNEL-positive ECV304 cells 72h after treatment with gemcitabine, radiotherapy, or the combination of gemcitabine and radiotherapy.
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s2000; Fukuoka et al, 2001; Lawrence et al, 2001; Liu et al,2 0 0 1 ) .
However, this might be the case only in some tumour types and
might occur either as a primary event induced by therapy or as a
secondary event after lethal damage to the cell (Brown and Wouters,
2001; Tannock and Lee, 2001) Increased induction of apoptosis is
observed with the radiosensitising effect of taxanes (Creane et al,
1999), vinorelbine (Fukuoka et al,2 0 0 1 ;Z h a n get al,2 0 0 4 ) ,
campthotecin (Rich, 2003), and oxaliplatin (Hermann et al, 2008).
However, clinical data do not provide definitive evidence for the role
of apoptosis in the response to cancer therapy, and in fact
contradicting reports were published, also concern the apoptotic
pathway (Brown and Wilson, 2003). Although some studies assign a
key role for the mitochondrial pathway in drug-induced apoptosis
and the death-receptor pathway may amplify this, other studies
suggest that mitochondria may act as amplifiers, but not initiators of
cell death (Debatin and Krammer, 2004; Fulda and Debatin, 2006).
However, further insight into the complex signalling network
activated in response to anticancer therapy is necessary to see to
what extent the current knowledge can be exploited for the design of
new cancer therapies (Fulda and Debatin, 2006).
As showed earlier, a clear radiosensitising effect has been
observed when gemcitabine treatment precedes irradiation
(Shewach and Lawrence, 1996; Pauwels et al, 2005a). It has also
been shown that the cell cycle effect of gemcitabine, being a block
in the early S-phase, is correlated with the radiosensitising effect
(Pauwels et al, 2005a). In this study the cell cycle progression after
treatment with the combination of gemcitabine and radiotherapy
initially resulted in an early S-phase block, after which the cells
progressed through the cell cycle. Seventy-two hours after
treatment, the cell cycle distribution returned to pre-treatment
levels. We observed that the amount of cells in culture had
decreased at that time and because the S-phase is not the most
radiosensitive phase (Sinclair, 1972; Tang et al, 1997), we
hypothesised that the blocked S-phase cells underwent apoptosis.
An increased induction of apoptosis was observed using radio-
sensitising conditions as determined by Annexin V staining,
caspase 3 activity assay, and TUNEL assay. When gemcitabine
followed radiation, less apoptotic cells were observed. This
schedule did not result in a radiosensitising effect either. It
seemed that apoptosis was induced after completion of S and G2/M
phase and that the cell cycle perturbations followed by the
induction of apoptosis play an important role in the radio-
sensitising effect. Wachters et al have shown that gemcitabine
causes radiosensitisation by specific interference with homologous
recombination-mediated repair and that homologues recombina-
tion repair is preferentially used in late S and G2 phases of the cell
cycle (Wachters et al, 2003), supporting our observations that
apoptosis was induced after completion of these cell cycle phases.
Gemcitabine is known to induce apoptosis by itself when used in
cytotoxic concentrations (Huang and Plunkett, 1995b; Huang et al,
1997). However, additional involvement of apoptosis in the
radiosensitising effect of gemcitabine has been reported also
(Doyle et al, 2001; Lawrence et al, 2001; Zhang et al, 2004) and our
findings are consistent with these reports. Lawrence et al
concluded indeed that apoptosis plays an important role in
gemcitabine-mediated radiosensitisation, but considered this not
to be the sole mechanism responsible for radiosensitisation, based
on the findings that the largest effect was observed in the
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sapoptotic-prone HT-29 cells and only modest apoptosis in
UMSCC-6 and A549 cells (Lawrence et al, 2001). Lawrence et al
and Doyle et al showed that it is a misconception that a defect in
apoptosis should restore a treatment-responsive state to the cell.
They showed that cell death occurs according to the mode of death
intrinsic to the cell line (Doyle et al, 2001; Lawrence et al, 2001). In
our study, a correlation was found between the increase in
apoptotic cells and the cell survival obtained with the SRB test with
the IC25 concentrations of gemcitabine. The lesser response of
H292 cells using the SRB test in Figure 1 in correlation with
apoptosis induction may be explained by the different determina-
tion times; that is apoptosis was determined 72h after treatment,
whereas cell survival is determined after 7 days.
The study of Lawrence et al only investigated the terminal parts
of the apoptotic pathway (caspase 3 activation and morphological
changes). Apoptosis can results from the activation of several
upstream pathways including TNF-receptor stimulation and
mitochondrial release of cytochrome c (Green, 1998). The second
part of our study was to determine which of these pathways were
activated during radiosensitisation, because the possibility re-
mained that selective potentiation of the active pathway could
increase the effectiveness of gemcitabine as a radiation sensitiser
(Lawrence et al, 2001).
Using radiosensitising conditions, both active caspase 8 and 9
could be observed by western blot. Therefore, the mitochondrial
membrane potential was measured. These experiments confirmed
the involvement of the mitochondria after treatment of the cells with
the combination of gemcitabine and radiotherapy and because of
these results, it seemed that gemcitabine and radiotherapy initially
activated the extrinsic apoptosis pathway, but that amplification of
this apoptosis signal by the mitochondrial pathway seemed
required. Therefore, the activation of Bid protein was determined.
Bid provides the only known connection between the extrinsic and
the intrinsic pathways (Kuribayashi and El-Deiry, 2008). Unfortu-
nately, the activated form tBid could not be observed. To further
investigate in depth the pathway induced by radiosensitising
conditions of gemcitabine, an apoptosis PCR array was performed.
We could show that gene expression after treatment with
gemcitabine and radiation was comparable with gene expression
after treatment with TRAIL. This was significant in ECV304 cells.
The similarity was less for H292 cells. TRAIL is a known inducer of
the extrinsic apoptosis pathway (Thorburn, 2007). This could mean
that in ECV304 cells (mt p53), the increased induction of apoptosis
after the combination of gemcitabine and radiotherapy is a result of
the activation of the extrinsic apoptosis pathway, whereas in H292
cells, which are wt p53 cells, this pathway is very likely activated, but
another apoptosis pathway must be involved also. Tolis et al showed
that gemcitabine exerts its antitumour effect by the apoptotic
machinery both in wt and mt p53 cells, indicating the presence of
p53 independent pathways (Tolis et al, 1999). The difference
between the two cell lines was also observed when we looked to the
genes that were significantly higher expressed in treated cells
(Figure 4B). In H292 cells, GADD45A, caspase 8, and Fas were
expressed more pronounced after treatment with gemcitabine and
radiotherapy, and it is known that these genes are transcriptionally
regulated by p53. GADD45A can also be induced by p53
independent mechanisms after DNA damage (source: http://
www.ncbi.nlm.nih.gov/pubmed/, 2008) as observed in ECV304 cells.
Using the PCR array, we observed an increase in expression of Bid
in ECV304 cells after using radiosensitising conditions, whereas we
could not observe this using a western blot. Most of the upregulated
genes are involved in a caspase-dependent programmed cell death.
Studies investigating the mechanism of apoptosis induction after
gemcitabine treatment alone have been published with variable
outcome. Most studies showed the involvement of the death receptor
pathway. Pace et al and Gazzaniga et al showed that gemcitabine
controls tumour progression by an increased sensitivity of tumour
cells to Fas-dependent apoptosis (Pace et al, 2000; Gazzaniga et al,
2007). However, Ferreira et al showed caspase 8 activation
independently from Fas/fasL signalling (Ferreira et al, 2000b) and
concluded that caspase 8 forms the apical and mitochondria-
dependent step that subsequently activates downstream caspases
(Ferreira et al, 2000a). In multiple myeloma cell lines, it was shown
that gemcitabine induced apoptosis with caspase 3, 8, 9, and PARP
cleavage, indicating that several mechanisms of action, including death
receptor pathway and mitochondrial damage, are involved (Nabhan
et al, 2002). In addition, in pancreatic cells, caspase 8 was activated
before the breakdown of the mitochondrial transmembrane potential
(Christgen et al, 2005). However, though these studies are in line with
our observations, other studies found the involvement of other
apoptotic signalling pathways (Chang et al, 2004; Habiro et al, 2004;
Schniewind et al, 2004; Kurdow et al, 2005; Okamoto et al,2 0 0 7 ) .
In summary, we could grant a role for the cell cycle
perturbations and for the induction and mechanism of apoptosis
in the radiosensitising effect of gemcitabine. It seems that the
combination of gemcitabine and radiotherapy activates the
extrinsic apoptosis pathway. The involvement of caspase 9, the
intrinsic pathway, is a secondary event, possibly resulting in an
enhancement of apoptosis. Apoptosis induction was very similar to
the apoptotic pathway after TRAIL treatment. Because gemcitabine
can enhance TRAIL-induced apoptosis (Seol et al, 2007), the use of
gemcitabine with TRAIL combined with radiation could be
promising. However, apoptosis does not represent the sole killing
mechanism by which cancers are eradicated, and other modes of
cell death, that is necrosis, autophagy, and mitotic catastrophe, are
some forms of cell death that cannot be easily classified at present,
and have to be considered also (Debatin and Krammer, 2004; Fulda
and Debatin, 2006). The primary mechanisms behind gemcitabines
radiosensitisation do not necessarily invoke the apoptotic
machinery. Impairment of double strand break repair through
the homologous recombination pathway (Wachters et al, 2003) or
futile mismatch repair cycles at replication forks (because of
precursor imbalance), or both may provoke apoptosis or result in
mitotic catastrophe. Different forms of cell death should be
considered when addressing the question of radiation-induced cell
damage or cell survival after irradiation (Abend, 2003).
This study reveals important new insights into the mechanism of
radiosensitisation, and can form a solid basis for further studies on
the role of apoptosis signalling molecules in clinical samples using
DNA or proteomic arrays. These studies are warranted to assess the
impact of these molecular parameters on clinical outcome.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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